SCNX — Scienture Holdings, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1382574 ·
Last close
$2.76
Market Cap
$113.34M
52W High
$18.75
52W Low
$2.64
ADV30
47,928
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,254,577 1,019,949 -5,723,506 -6,009,447 87,184,306 4,747,439 28,440,722
Jun 2026 343,639 335,779 -2,699,733 -2,822,371 87,734,007 8,188,140 23,632,481
Mar 2026 56,325 53,850 -3,509,499 -3,402,264 80,661,705 3,542,754 13,841,265
Dec 2025 -168,699 -243,812 -3,154,363 -28,120,333 84,178,330 6,662,008 14,057,946

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,443,375
Investing CF
$0
Financing CF
$25,625,596
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-86,775,872
Inventory
$203,074
Receivables
$385,313
ST Investments
—
EBIT TTM
$-36,881,474
Pretax Income TTM
$-39,947,207
Interest Exp TTM
$3,065,733
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$821,315
EBITDA
$-12,361,262
Free Cash Flow
$-7,611,433
Enterprise Value
$16,787,558
Total Cash
$8,188,140
Total Debt
$10,689,481
Shares Out
41,064,146
Trailing EPS
$-2.03
Book Value
$1.56
ROE
-53.5%
ROA
-8.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 431,609 -16,244,792 -41,512,264 84,178,330 14,057,946 70,120,384 -13,379,683
Dec 2024 136,643 -14,701,015 9,065,798 104,853,805 25,781,684 79,072,121 -14,265,238
Dec 2023 1,363,830 -4,396,451 -17,843,574 12,532,913 11,990,560 542,353 -2,225,192
Dec 2022 10,250,168 -2,040,719 -3,472,099 3,710,026 3,367,159 763,136 -1,564,668
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$821,315
NetIncome TTM
$-37,952,329
OpCashFlow TTM
—
Assets (Latest)
$87,734,007
Forward EPS
$0.00

Peers — same industry

TickerNameMarket CapLastDaily %
UPB Upstream Bio, Inc. $115.10M $2.10 —
AKBA Akebia Therapeutics, Inc. $111.18M $0.40 —
SPRB SPRUCE BIOSCIENCES, INC. $116.37M $40.49 —
FHTX Foghorn Therapeutics Inc. $109.73M $1.83 —
NRXP NRX Pharmaceuticals, Inc. $106.07M $2.45 —

News headlines (Yahoo Finance, 1h cache)

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
2026-11-16 13:30 · Yahoo
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
2026-10-22 12:05 · Yahoo
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
2026-10-13 12:05 · Yahoo
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
2026-10-13 11:45 · Yahoo
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
2026-10-02 12:05 · Yahoo
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
2026-10-02 11:46 · Yahoo
Scienture Holdings, Inc. Announces Reverse Stock Split
2026-09-30 20:05 · Yahoo
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
2026-09-22 12:15 · Yahoo
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
2026-06-18 12:05 · Yahoo
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
2026-06-02 12:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.